Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy gene therapy race. The biotech reported expectation-busting phase 1 data on its next-generation candidate, sending its stock spiralling upward.
Solid Biosciences has surged back into the Duchenne muscular dystrophy gene therapy race. The biotech reported expectation-busting phase 1 data on its next-generation candidate, sending its stock spiralling upward.
